Search

Rigel Pharmaceuticals Inc

Închisă

SectorSănătate

44.88 -2.18

Rezumat

Modificarea prețului

24h

Curent

Minim

45.88

Maxim

45.92

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+41.64% upside

Dividende

By Acuity

Următoarele câștiguri

3 nov. 2026

Sentimentul știrilor

By Acuity

28%

72%

80 / 340 Clasament în Healthcare

Rigel Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 aug. 2026, 19:36 UTC

Rigel Pharmaceuticals Inc is trading higher, despite pulling back from an earlier session peak. The stock remains above its 20-day moving average.

20 aug. 2026, 20:06 UTC

Rigel Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday amid broader market pressures, though no specific news has been identified.

19 aug. 2026, 20:02 UTC

Rigel Pharmaceuticals Inc is trading higher amid strong market activity and high volume, reflecting increased investor interest since Tuesday's close.

18 aug. 2026, 22:01 UTC

Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.

17 aug. 2026, 20:06 UTC

News

Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.

14 aug. 2026, 20:06 UTC

Event
News

HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.

13 aug. 2026, 19:16 UTC

News
Event

Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.

11 aug. 2026, 20:06 UTC

Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.

7 aug. 2026, 19:26 UTC

News

Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.

6 aug. 2026, 20:06 UTC

News

Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.

5 aug. 2026, 20:02 UTC

News

Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.

4 aug. 2026, 23:01 UTC

News

Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.

3 aug. 2026, 19:26 UTC

Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.

31 iul. 2026, 19:41 UTC

Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.

30 iul. 2026, 19:29 UTC

Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.

29 iul. 2026, 19:47 UTC

Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.

28 iul. 2026, 19:56 UTC

News

Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.

27 iul. 2026, 16:16 UTC

Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.

24 iul. 2026, 20:01 UTC

Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.

22 iul. 2026, 20:06 UTC

Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.

21 iul. 2026, 17:26 UTC

News

Rigel Pharmaceuticals Inc shares are higher, reflecting positive sentiment in the biotechnology sector amid broader market gains, particularly in technology stocks.

Comparație

Modificare preț

Rigel Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

41.64% sus

Prognoză pe 12 luni

Medie 65 USD  41.64%

Maxim 85 USD

Minim 43 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRigel Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

2

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

80 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

$

help-icon Live chat